urine-based cancer detection
Bringing clarity and precision to cancer diagnostics through advanced nanoscale imaging and machine learning
ABOUT US
Cellens is pioneering in label-free cell analysis with nanoscale imaging and machine learning
ADDRESSING UNMET NEEDS
IN NON-INVASIVE CANCER DETECTION

VOIDED
URINE FIXATION

STANDARD LAB
PROCESSING

HIGH RESOLUTION CELL SURFACES IMAGING

MACHINE LEARNING ANALYSIS TO DETECT MALIGNANCY

PATIENT MONITORING
High recurrence (50-80%) from non-muscle-invasive bladder cancer (NMIBC, 75% of all bladder cancer cases) requires invasive surveillance exams every 3 to 6 months. The exam, cystoscopy, consists of inserting a physical probe into the bladder through the urethra so that urologists can inspect for lesions, resulting in high lifetime costs, low patient compliance, and complications from trauma to the urethra (i.e: UTIs)
Cellens introduces a high accuracy urine-based test that would reduce the frequency of invasive procedures like cystoscopy needed to monitor bladder cancer and aims to set a new standard in bladder cancer diagnostics.
Cellens to receive “Bit to Bytes” award from Baker-Polito Administration and the Massachusetts Life Sciences Center
Fourteen projects receiving funding to support R&D, innovation in addressing challenges in therapeutic delivery and unlocking potential of data science to answer pressing life sciences questions